Table 2. Clinicopathological features of patients with squamous and adenosquamous cell lung carcinoma with ALK rearrangement and comparisons of PFS from previous clinical studies.
| Present cases* | Age/ sex |
Smoking history |
Cancer type | Stage | IHC for Sq diagnosis | ALK-rearrangement detection | ALK inhibitor | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PY | Sq or AdSq | p40 | p63 | TTF−1 | Napsin A | IHC | % Positive FISH | First regimen |
PFS (mo) |
Second regimen |
PFS (mo) |
Third Regimen |
PFS (mo) |
||||
| CASE 1 | 64/F | 0 | AdSqa | IV | + | + | − | − | + | + | 94 | Crizotinib | 7 | Alectinib | 4 | Ceritinib | 8 |
| CASE 2 | 65/F | 25 | Sq | IV | + | + | − | − | − | + | 78 | Crizotinib | 2 | Alectinib | 1 | Ceritinib | 0.5 |
| CASE 3 | 36/M | 23 | Sq | IIIB | + | + | − | N/A | + | + | 86 | Crizotinib | 12 | Alectinib | 5 | N/A | N/A |
| CASE 4 | 62/M | 21 | Sq | IV | + | + | − | N/A | − | + | 21 | Crizotinib | 1 | N/A | N/A | N/A | N/A |
| CASE 5 | 47/M | 20 | AdSq | IV | + | + | + | N/A | + | + | 66 | Crizotinib | 9 | N/A | N/A | N/A | N/A |
| Mean PFS | 6.2 | Mean PFS | 3.3 | ||||||||||||||
| Clinical studies | |||||||||||||||||
| PROFILE1007 [2] | Crizotinib | 7.7 | |||||||||||||||
| PROFILE1014 [3] | Crizotinib | 10.9 | |||||||||||||||
| AF−001JP [4] | Alectinib | >29 | |||||||||||||||
| NP28673 [5] | Alectinibb | 8.9 | |||||||||||||||
| ASCEND−2 [6] | Ceritinibb | 5.7 | |||||||||||||||
| ASCEND−3 [7] | Ceritinib | 13.8 | |||||||||||||||
AdSq, adenosquamous; ALK, anaplastic lymphoma kinase; F, female; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; M, male; mo, month; N/A, not available; PFS, progression-free survival; PY, pack year; Sq, squamous.
aCytology from pleural effusion showed lung adenocarcinoma (p40−/p63−/TTF-1+).
bAfter crizotinib resistance.
*Cases 4 and 5 were added from Juntendo Urayasu Hospital.